Ryan Bartolucci Sells 1,834 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 1,834 shares of Tempus AI stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $65.54, for a total value of $120,200.36. Following the completion of the sale, the chief accounting officer directly owned 44,061 shares of the company’s stock, valued at approximately $2,887,757.94. This represents a 4.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Tempus AI Stock Down 4.9%

NASDAQ TEM traded down $3.40 during trading hours on Thursday, hitting $65.69. 7,149,431 shares of the company’s stock were exchanged, compared to its average volume of 6,352,496. The business’s 50 day moving average is $83.96 and its 200-day moving average is $71.87. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28. Tempus AI, Inc. has a 12-month low of $31.36 and a 12-month high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The company had revenue of $334.21 million during the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company’s quarterly revenue was up 84.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.46) EPS. Tempus AI has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

Several large investors have recently added to or reduced their stakes in TEM. Cranbrook Wealth Management LLC acquired a new stake in shares of Tempus AI during the third quarter worth $25,000. Concord Wealth Partners boosted its holdings in shares of Tempus AI by 308.0% in the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after buying an additional 308 shares during the period. JPL Wealth Management LLC bought a new stake in shares of Tempus AI during the 3rd quarter valued at about $26,000. GAMMA Investing LLC acquired a new stake in Tempus AI during the third quarter worth about $28,000. Finally, Allworth Financial LP raised its stake in Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after acquiring an additional 450 shares during the period. 24.22% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TEM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a research note on Wednesday, October 8th. Needham & Company LLC lifted their price target on shares of Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Piper Sandler reduced their price objective on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. Cowen lowered shares of Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Finally, Morgan Stanley boosted their target price on shares of Tempus AI from $68.00 to $80.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tempus AI presently has a consensus rating of “Hold” and a consensus price target of $80.00.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.